ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.4947_4948del (p.Pro1651fs) (rs80359474)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000131072 SCV000186002 pathogenic Hereditary cancer-predisposing syndrome 2016-09-16 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Breast Cancer Information Core (BIC) (BRCA2) RCV000113361 SCV000146511 pathogenic Breast-ovarian cancer, familial 2 2004-02-20 no assertion criteria provided clinical testing
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000113361 SCV000327109 pathogenic Breast-ovarian cancer, familial 2 2015-10-02 criteria provided, single submitter clinical testing
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000113361 SCV000300806 pathogenic Breast-ovarian cancer, familial 2 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
GeneDx RCV000478026 SCV000567519 pathogenic not provided 2018-08-21 criteria provided, single submitter clinical testing This deletion of two nucleotides in BRCA2 is denoted c.4947_4948delAA at the cDNA level and p.Pro1651CysfsX14 (P1651CfsX14) at the protein level. The normal sequence, with the bases that are deleted in brackets, is CAAA[delAA]GTCC. The deletion causes a frameshift, which changes a Proline to a Cysteine at codon 1651, and creates a premature stop codon at position 14 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA2 c.4947_4948delAA, previously reported as 5175delAA using alternate nomenclature, has been observed in individuals with breast, ovarian, and/or pancreatic cancer (Walsh 2011, Zhen 2015). We consider this variant to be pathogenic.
Invitae RCV000044529 SCV000072542 pathogenic Hereditary breast and ovarian cancer syndrome 2018-05-08 criteria provided, single submitter clinical testing This sequence change deletes 2 nucleotides from exon 11 of the BRCA2 mRNA (c.4947_4948delAA), causing a frameshift at codon 1651. This creates a premature translational stop signal (p.Pro1651Cysfs*14) and is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic.  This particular variant has been reported in an individual affected with ovarian cancer (PMID: 22006311). This variant is also known as (c.5175delAA, p.Lys1649fsX15) in the literature. ClinVar contains an entry for this variant (Variation ID: 51747). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.